Discovery of 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as potent and selective CDK9 inhibitors that enable transient target engagement for the treatment of hematologic malignancies-Reference-Cited by-同舟云学术

Discovery of 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as potent and selective CDK9 inhibitors that enable transient target engagement for the treatment of hematologic malignancies

Published:2022-08 Issue: Volume:238 Page:114461
ISSN:0223-5234
Container-title:European Journal of Medicinal Chemistry
language:en
Short-container-title:European Journal of Medicinal Chemistry

Author:

Wang Xinren,Liu Xiaoyue,Huang Jianhang,Liu Chenhe,Li Hongmei,Wang Cong,Hong Qianqian,Lei Yan,Xia Jiawei,Yu Ziheng,Dong Ruinan,Xu Junyu,Tu Zhenlin,Duan ChunQi,Li Shuwen,Lu Tao,Tang Weifang,Chen Yadong^ORCID

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Pharmacology,General Medicine

Reference21 articles.

1. Inhibitors of cyclin-dependent kinases as cancer therapeutics;Whittaker;Pharmacol. Ther.,2017

2. Hallmarks of cancer: the next generation;Hanahan;Cell,2011

3. Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism;Lu;Elife,2015

4. Therapeutic targeting of transcriptional cyclin-dependent kinases;Galbraith;Transcription,2019

5. Suppression of myeloid cell leukemia-1 (Mcl-1) enhances chemotherapy-associated apoptosis in gastric cancer cells;Akagi;Gastric Cancer,2013

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of novel flavonoid-based CDK9 degraders for prostate cancer treatment via a PROTAC strategy;European Journal of Medicinal Chemistry;2023-11

2. Design and optimization of selective and potent CDK9 inhibitors with flavonoid scaffold for the treatment of acute myeloid leukemia;European Journal of Medicinal Chemistry;2023-11

3. Design, Synthesis, Antitumour Evaluation, and In Silico Studies of Pyrazolo-[1,5-c]quinazolinone Derivatives Targeting Potential Cyclin-Dependent Kinases;Molecules;2023-09-13

4. A patent review of selective CDK9 inhibitors in treating cancer;Expert Opinion on Therapeutic Patents;2023-04-03

5. Exploring the cytotoxic effect and CDK-9 inhibition potential of novel sulfaguanidine-based azopyrazolidine-3,5-diones and 3,5-diaminoazopyrazoles;Bioorganic Chemistry;2023-04